Presence of Ascites at Presentation is Associated With Absence of Long-Term Response Amongst Patients With Budd-Chiari Syndrome When Treated With Medical Therapy Alone: A Single Centre Real-Life Experience
Tài liệu tham khảo
Plessier, 2006, Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome, Hepatology, 44, 1308, 10.1002/hep.21354
Seijo, 2013, European Network for Vascular Disorders of the Liver. Good longterm outcome of Budd-Chiari syndrome with a step-wise management, Hepatology, 57, 1962, 10.1002/hep.26306
Zeitoun, 1999, Outcome of Budd–Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting, Hepatology, 30, 84, 10.1002/hep.510300125
Linkins, 2003, Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a metaanalysis, Ann Intern Med, 139, 893, 10.7326/0003-4819-139-11-200312020-00007
Malinchoc, 2000, A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts, Hepatology, 31, 864, 10.1053/he.2000.5852
Darwish Murad, 2004, Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome, Hepatology, 39, 500, 10.1002/hep.20064
Rathod, 2017, Endovascular treatment of budd chiari syndrome: single centre experience, J Gastroenterol Hepatol, 32, 237, 10.1111/jgh.13456
Min, 1997, Reassessing the role of medical therapy in the management of hepatic vein thrombosis, Liver Transplant Surg, 3, 423, 10.1002/lt.500030410
Sakr, 2017, Validation of prognostic indices in Egyptian Budd-Chiari syndrome patients: a single-center study, World J Gastroenterol, 23, 629, 10.3748/wjg.v23.i4.629
Qi, 2015, Survival and prognostic indicators of Budd–Chiari syndrome: a systematic review of 79 studies, Expet Rev Gastroenterol Hepatol, 9, 865, 10.1586/17474124.2015.1024224